drugset

drugset / Trial / NCT01781455

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

NCT01781455 ↗

Phase 1 Completed 311 enrolled Sumitomo Pharma America, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, single arm dose escalation study of BBI503 in adult patients with advanced solid tumors.

Timeline

Start: 2012-02
Primary completion: 2020-06
Completion: 2020-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMCASERTIB	Small molecule	—	—

Indications